menu
    • menu
    [{"orgOrder":0,"company":"Vega Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"VGA039","moa":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Vega Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Vega Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Vega Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Vega Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"VGA039","moa":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Vega Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Vega Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Vega Therapeutics \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Vega Therapeutics

    Menu

    Vega Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Vega Therapeutics

                            U.S.A arrow
                            The Pharmacy Technology
                            Not Confirmed

                            Vega Therapeutics

                            U.S.A arrow
                            The Pharmacy Technology
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VGA039

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Vega Therapeutics Receives FDA Orphan Drug Designation for VGA039 for the Treatment of von Willebrand Disease

                            Details : VGA039 is a first-in-class antibody therapy that modulates Protein S, a key co-factor involved in thrombin generation during both initiation and propagation of coagulation, it had demonstrated efficacy in numerous congenital bleeding disorders, including...

                            Brand Name : VGA039

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 23, 2023

                            Lead Product(s) : VGA039

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Vega Therapeutics

                            U.S.A arrow
                            The Pharmacy Technology
                            Not Confirmed

                            Vega Therapeutics

                            U.S.A arrow
                            The Pharmacy Technology
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VGA039

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Vega Therapeutics Initiates Clinical Trial Program for VGA039, a First‑in‑Class Antibody Therapy for von W...

                            Details : VGA039 is a first-in-class antibody therapy that modulates Protein S, a key co-factor involved in thrombin generation during both initiation and propagation of coagulation, it had demonstrated efficacy in numerous congenital bleeding disorders, including...

                            Brand Name : VGA039

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            April 06, 2023

                            Lead Product(s) : VGA039

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth